Spelling suggestions: "subject:"aml"" "subject:"am1""
1 |
Identification de gènes ciblès par ETV6-AML1, un facteur de transcription chimérique retrouvé dans la leucémie de l'enfantLanglois, Sylvie January 2005 (has links)
Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.
|
2 |
The role of TLE4 as a tumor suppressor in acute myeloid leukemia and regulator of hematopoietic and bone developmentShin, Thomas H. 06 February 2017 (has links)
The presence of AML1-ETO (RUNX1-CBF2T1), a fusion oncoprotein resulting from a t(8;21) chromosomal translocation, is a necessary but insufficient event in the development of a subset of acute myeloid leukemias (AML). Although AML1-ETO is able to block differentiation and immortalize hematopoietic stem cells, other contributory events are required for cell proliferation and leukemogenesis, suggesting that specific tumor suppressor genes may counteract the leukemic potential of AML1-ETO.
In studying del(9q), one of the most common concomitant chromosomal abnormalities with t(8;21), we identified the loss of TLE4 as a key cooperating event in the development of AML1-ETO AML, leading to increased cell proliferation, blocked apoptosis and differentiation, as well as cytarabine resistance in leukemic cells. This suggested TLE4 functions as a tumor suppressor gene in AML.We found these effects are mediated by the loss of TLE4 regulation of a COX-Wnt inflammatory axis. These effects were consequently reversible by Wnt signaling and cyclooxygenase inhibition, pointing towards anti-inflammatory agents as potentially new therapeutic and adjuvant strategies for AML.
While studies in Drosophila implicate TLE/Groucho as a key mediator of various signaling pathways, including receptor tyrosine kinase/Ras/MAPK, Notch, Myc, and Wnt pathways, there is surprisingly little known about the role of TLE in mammalian development. Using a Tle4 knockout (T4KO) mouse, we identified previously unknown roles for Tle4 in regulating vertebrate mammalian hematopoietic and bone development. T4KO mice manifest leukocytopenia and defective hematopoietic stem cell populations. Using serial transplantation and stromal co-culture, we find that these hematopoietic deficiencies arise due to both intrinsic dysfunction of hematopoietic stem cells as well as defective extrinsic regulation of hematopoiesis by the stem cell niche. Additionally, T4KO mice are severely runted and exhibit markedly decreased bone mineralization concomitant with defective osteoblast function and decreased mineral apposition rates.
Many of the pathways regulated by TLE are aberrant in cancer, which has led to increasing studies connecting TLE with various malignancies, including synovial cell sarcoma and glioblastoma. Our findings have great implications for current understanding of TLE function in not only cancer, but also bone and hematopoietic development.
|
3 |
The role of THPO/MPL signaling in AML1-ETO self-renewalGriesinger, Andrea January 2011 (has links)
No description available.
|
4 |
Modeling and Analysis of Acute Leukemia using Human Hematopoietic Stem and Progenitor CellsLin, Shan January 2016 (has links)
No description available.
|
5 |
Novel mechanisms of transcriptional regulation by leukemia fusion proteinsGow, Chien-Hung, M.D. 17 October 2014 (has links)
No description available.
|
6 |
Survival is an essential component of self-renewal induced by a Class II leukemia oncogeneChou, Fu-Sheng, M.D. 20 September 2011 (has links)
No description available.
|
7 |
RUNX1/AML1 functions and mechanisms regulating granulocyte-macrophage colony-stimulating factor transcriptionLiu, Hebin January 2005 (has links)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multipotent cytokine involved in the production and function of hematopoietic cells, and GM-CSF plays in particular a major role in responses to infection and physiological and pathological inflammatory processes. GM-CSF is produced in many cell types, and increases in the intracellular Ca2+ concentration are, like in many other systems, of major importance in the intracellular signaling that determines GM-CSF expression after receptor stimulation of the cells. Previous studies have shown that the Ca2+/calmodulin-dependent phosphatase calcineurin (CN) mediates stimulation of GM-CSF transcription in response to Ca2+. This thesis shows that Ca2+ signaling also regulates GM-CSF transcription negatively through Ca2+/calmodulin-dependent kinase II (CaMK II) phosphorylation of serines in the autoinhibitory domain for DNA binding of the transcription factor Ets1. Mutation of the CaMK II target serines increased transactivation of the GM-CSF promoter/enhancer and decreased the sensitivity to inhibition by increased Ca2+ or constitutively active CaMK II. The Ca2+-dependent phosphorylation of Ets1 was also shown to reduce the binding of Ets1 to the GM-CSF promoter in vivo. RUNX1, also known as acute myeloid leukemia 1 (AML1), is one of three mammalian RUNX transcription factors and has many essential functions in hematopoiesis. RUNX1 has also many important roles in the immune system, and RUNX1 is the most frequent target for chromosomal translocation of genes in acute human leukemias. This thesis shows that RUNX1 directly interacts with both subunits of CN and that the strongest interaction is localised to the regulatory CN subunit and the DNA binding domain of the RUNX protein. Constitutively active CN was shown to activate the promoter/enhancer of GM-CSF synergistically with RUNX1, RUNX2 or RUNX3, and the Ets1 binding site of the promoter was shown to be essential for the synergy between RUNX1 and CN in Jurkat T cells. The analysis suggests that Ets1 phosphorylated by the protein kinase glycogen synthase kinase-3β is the target of RUNX1-recruited CN phosphatase at the GM-CSF promoter. Transforming growth factor-β (TGF-β) is another multipotent cytokine that often has a role opposite to that of GM-CSF in inflammatory responses since it is a potent suppressor of immune cells and therefore is anti-inflammatory. This thesis shows that TGF-β can decrease transcription from a GM-CSF promoter/enhancer. Certain constitutively active TGF-β receptors and the TGF-β activated transcription factor Smad3 could also repress GM-CSF transcription, whereas several other Smad proteins did not have this inhibitory effect. The inhibition required intact DNA binding ability of Smad3, and the 125 bp upstream of the transcription initiation site, which was sufficient for the inhibition, contains several weak Smad binding sites near the TATA box next to an Ets1 site of the promoter. Smad3 was able to bind to the promoter DNA together with Ets1 and could also be in complex with Ets1 in the absence of DNA. Surface plasmon resonance analysis revealed that Ets1 interacted with the DNA binding domain of Smad3, and the binding constant of this interaction was about 1 µM. The results identify a negative regulation of the GM-CSF promoter by TGF-β signaling through direct Smad3 binding and indicate that the mechanism is by Smad3 interaction with Ets1 and perhaps other proteins around the TATA box of the promoter. This thesis also identifies a novel transactivation domain in the N-terminal of RUNX1 including the N-terminal α-helix in the DNA binding domain. The domain was also required for RUNX2 and RUNX3 transactivation. Despite this, the N-terminal domain of RUNX1 was not essential for RUNX1 function in megakaryocytopoiesis in vitro from mouse embryonic stem cells.
|
8 |
Role fúzního proteinu ETV6-RUNX1 v citlivosti leukemických buněk na L-asparaginázu / The role of ETV6-RUNX1 fusion protein in the sensitivity of leukemic cells to L-asparaginaseStaněk, Petr January 2018 (has links)
Translocation t(12;21) with the presence of the fusion gene ETV6-RUNX1 (TEL-AML1) is the most common chromosomal aberration found in acute lymphoblastic leukemia in childhood. The occurrence of the ETV6-RUNX1 is associated with excellent prognosis and high sensitivity to the treatment with the enzyme L-asparaginase (ASNase). Resistance to the drug aggravates the outlook of the patient and increases the risk of treatment failure, therefore, the CLIP working group has been for a long time involved in the identification of the mechanism of action of ASNase and the origin of the resistance to it. This thesis follows previous findings of the group and is devoted to the analysis of the importance of ETV6-RUNX1 and signalization and metabolic changes accompanying shifts in the L-asparaginase resistance. In the first part of the thesis, the knockout clones with stable increased resistance to ASNase have been established thanks to the CRISPR/Cas9 system, which created frameshift in the fusion gene. The accomplishment in this regard and removal of the fusion protein was confirmed on the level of DNA, mRNA a protein expression. The presence of other significant chromosomal aberrations affection the sensitivity to ASNase was ruled out by the means of SNP analysis. In the second part of the project, the signalization...
|
9 |
Role fúzního proteinu ETV6-RUNX1 v citlivosti leukemických buněk na L-asparaginázu / The role of ETV6-RUNX1 fusion protein in the sensitivity of leukemic cells to L-asparaginaseStaněk, Petr January 2018 (has links)
Translocation t(12;21) with the presence of the fusion gene ETV6-RUNX1 (TEL-AML1) is the most common chromosomal aberration found in acute lymphoblastic leukemia in childhood. The occurrence of the ETV6-RUNX1 is associated with excellent prognosis and high sensitivity to the treatment with the enzyme L-asparaginase (ASNase). Resistance to the drug aggravates the outlook of the patient and increases the risk of treatment failure, therefore, the CLIP working group has been for a long time involved in the identification of the mechanism of action of ASNase and the origin of the resistance to it. This thesis follows previous findings of the group and is devoted to the analysis of the importance of ETV6-RUNX1 and signalization and metabolic changes accompanying shifts in the L-asparaginase resistance. In the first part of the thesis, the knockout clones with stable increased resistance to ASNase have been established thanks to the CRISPR/Cas9 system, which created frameshift in the fusion gene. The accomplishment in this regard and removal of the fusion protein was confirmed on the level of DNA, mRNA a protein expression. The presence of other significant chromosomal aberrations affection the sensitivity to ASNase was ruled out by the means of SNP analysis. In the second part of the project, the signalization...
|
10 |
Nachweis von TEL-Genrekombinationen mittels Southern Blot bei Kindern mit akuter lymphoblastischer LeukämieKothe, Blanka 10 July 2003 (has links)
Das in der vorliegenden Arbeit vorgestellte Verfahren der nicht-radioaktiven Southern Blot Hybridisierung unter Verwendung einer Digoxigenin Markierung hat sich für die Darstellung von Rekombinationen im TEL-Genlokus genomischer DNA als sensitive Vergleichsmethode bewiesen. Es wurden insgesamt 122 Kinder mit dieser Methode auf das Vorliegen der Translokation t(12;21) untersucht. Bei einer nur relevante Faktoren berücksichtigenden Beschränkung des PatientInnenkollektivs auf protokollgerecht nach ALL-REZ BFM behandelte B-Vorläufer-Zell-ALL und Erstrezidive konnte eine Rekombination von TEL in 5 von 65 PatientInnen (7,7%) nachgewiesen werden. Lässt man die Einschlusskriterien der ALL-REZ BFM Studie unberücksichtigt, handelt es sich sogar um 7 von 71 (9,9%) PatientInnen. Damit bestätigen die hier vorliegenden Ergebnisse den Trend der aktuellen Diskussion über die Häufigkeit des Vorliegens des Fusionsgenes TEL-AML1 bei Erstrezidiven, die eine kumulative Inzidenz bei einem 10-jährigen Untersuchungszeitraum von 9 ± 5% angeben. Weiterhin konnte mit ereignisfreien Beobachtungszeiträumen nach dem 1. Rezidiv im Median von 8,6 Jahren ein Trend zu späten Rezidiven und somit eine mittelfristig günstige Prognose für die TEL-Rearrangement positiven Rezidivfälle konstatiert werden. Zusammenfassend kann gesagt werden, dass TEL-AML1 positive PatientInnen eine Subgruppe darstellen, die lange erkrankungsfreie Intervalle mit zur Zeit üblichen Therapieprotokollen erreichen, nach Therapie der Ersterkrankung aber auch nach dem ersten Rezidiv. Auf Grund der sich aus dem retrospektiven PatientInnekollektiv ergebenen Selektion war es nicht möglich, statistisch signifikante Aussagen zur unabhängigen prognostischen Bedeutung für die langfristige Prognose von ALL im Kindesalter mit TEL-Rekombinationen zu treffen. / The presence of TEL/AML1 fusion gene in childhood acute lymphoblastic leukaemia (ALL) defines a subgroup of patients with better than average outcome. Around 20% of the patient at point of initial ALL diagnosis are characterised by this fusion transcript from translocation t(12;21)(p12;q22). However, the prognostic significance of this aberration has recently been disputed by the Berlin-Frankfurt-Munster (BFM) study group due to its relatively high incidence found in relapsed patients (19.6% and 21.9%, in two cohorts). Here we wanted to get more data in a long term follow up retrospect investigation by analysing DNA from frozen conserved bone marrow samples of 65 children. In the study presented here only five out of 65 (7.7%) patients selected as childhood B cell precursor acute lymphoblastic leukaemia only treated according to Berlin-Frankfurt-Munster (BFM) ALL relapse trial protocols (ALL-REZ BFM 82-96) (excluding T-lineage and Philadelphia chromosome (Ph)-positive leukaemia) carry this fusion. The detection was done due to a new developed non-radioactive Southern blotting with a Digoxigenin marked template. We could confirm the still good middle term prognosis in the relapsed TEL-AML1 positive subgroup. The TEL-AML1-positive and negative patients differed with respect to duration of last remission and age at initial diagnosis. At a median follow-up time of 8.6 years, children positive for TEL-AML1 had a higher probability of disease-free survival. Because of the small number of patients in this study it was not possible to get statistical significant facts about the independent prognostic impact for the long term prognosis of ALL in childhood with TEL rearrangement.
|
Page generated in 0.0454 seconds